These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12800071)

  • 1. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.
    Sulkowski MS
    Semin Liver Dis; 2003 May; 23(2):183-94. PubMed ID: 12800071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
    Bruno R; Sacchi P; Maiocchi L; Patruno S; Filice G
    Dig Liver Dis; 2006 Jun; 38(6):363-73. PubMed ID: 16631422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus.
    Cooper CL; Parbhakar MA; Angel JB
    Clin Infect Dis; 2002 May; 34(9):1259-63. PubMed ID: 11941553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
    Kumar R; Singla V; Kacharya Sk
    Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
    Stone SF; Lee S; Keane NM; Price P; French MA
    J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
    Pineda JA; Macías J
    J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.
    Rose H; Woolley I; Hoy J; Dart A; Bryant B; Mijch A; Sviridov D
    Metabolism; 2006 Jan; 55(1):90-5. PubMed ID: 16324925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of hepatitis C in HIV-coinfection.
    Rockstroh JK; Vogel M
    Eur J Med Res; 2004 Jun; 9(6):304-8. PubMed ID: 15257871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
    Cooper CL; Mills E
    Int J STD AIDS; 2007 Aug; 18(8):546-50. PubMed ID: 17686217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Vogel M; Rockstroh JK
    Curr Opin HIV AIDS; 2009 May; 4(3):171-5. PubMed ID: 19532046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
    Mocroft A; Rockstroh J; Soriano V; Ledergerber B; Kirk O; Vinogradova E; Reiss P; Katlama C; Phillips AN; Lundgren JD;
    Antivir Ther; 2005; 10(7):779-90. PubMed ID: 16312175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.